| Title |
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
|
|---|---|
| Published in |
Patient preference and adherence, September 2010
|
| DOI | 10.2147/ppa.s10620 |
| Pubmed ID | |
| Authors |
Jon Ebbert |
| Abstract |
Smoking is the leading preventable cause of morbidity and mortality in the US, and decreasing smoking prevalence is a public health priority. Patients achieve the greatest success when quit attempts involve behavioral therapy combined with pharmacotherapy. Varenicline is the most recent addition to the pharmacotherapeutic armamentarium for the treatment of tobacco dependence. Varenicline is efficacious and cost-effective. Smoking relapse and adverse treatment-related side effects may decrease medication adherence and patient satisfaction with varenicline. In the clinical setting, varenicline treatment can be optimized by reducing doses in patients who experience intolerable side effects, increasing the dose in partial responders, and providing long-term maintenance therapy for relapse prevention. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | 40% |
| New Zealand | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 107 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 32 | 30% |
| Student > Master | 18 | 17% |
| Researcher | 9 | 8% |
| Student > Ph. D. Student | 7 | 7% |
| Other | 6 | 6% |
| Other | 13 | 12% |
| Unknown | 22 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 13% |
| Psychology | 7 | 7% |
| Nursing and Health Professions | 4 | 4% |
| Chemistry | 4 | 4% |
| Other | 17 | 16% |
| Unknown | 24 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 September 2020.
All research outputs
#1,337,168
of 23,577,654 outputs
Outputs from Patient preference and adherence
#50
of 1,654 outputs
Outputs of similar age
#4,342
of 95,828 outputs
Outputs of similar age from Patient preference and adherence
#1
of 4 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,654 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,828 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them